TScan Therapeutics Inc TCRX:NASDAQ

RT Quote | NASDAQ | USD
Last | 07/23/21 EDT
10.04quote price arrow up+0.07 (+0.70%)
Volume
91,052
52 week range
9.64 - 12.32

...

Loading . . .
  • Open10.45
  • Day High10.45
  • Day Low9.66
  • Prev Close9.97
  • 52 Week High12.32
  • 52 Week High Date07/16/21
  • 52 Week Low9.64
  • 52 Week Low Date07/22/21

Key Stats

  • Market Cap236.14M
  • Shares Out23.52M
  • 10 Day Average Volume0.00M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-

KEY STATS

  • Open10.45
  • Day High10.45
  • Day Low9.66
  • Prev Close9.97
  • 52 Week High12.32
  • 52 Week High Date07/16/21
  • 52 Week Low9.64
  • 52 Week Low Date07/22/21
  • Market Cap236.14M
  • Shares Out23.52M
  • 10 Day Average Volume0.00M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-

RATIOS/PROFITABILITY

  • EPS (TTM)-3.48
  • P/E (TTM)-2.89
  • Fwd P/E (NTM)-
  • EBITDA (MRQ)-
  • ROE (MRQ)-
  • Revenue (MRQ)-
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On TScan Therapeutics Inc

There is no recent news for this security.

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Tscan Therapeutics Inc is a United States-based preclinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. TScan is engaged in advancing a pipeline of TCR-T therapy candidates for the treatment of patients with hematologic and solid tumor malignancies. Its lead liquid tumor product candidates, TSC-100 and TSC-101, are under development for the...
David Southwell
Chief Executive Officer
Ann Hargraves
Vice President
Shane Maltbie CPA
Vice President - Finance
Address
830 Winter Street
Waltham, MA
02451
United States